ArticleOpen Access http://dx.doi.org/10.26855/ijcemr.2025.11.006
Efficacy and Safety Analysis of Recombinant Human Interferon Alpha-2b Combined with Hydroxyurea Tablets in the Treatment of MPN
Yigang Guo, Lulu Zhang*, Ping Hu, Xiu Guo, Rongyao Zhang, Na Li, Qiong Yi, Xu Chen
Department of Stomatology, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, China.
*Corresponding author: Lulu Zhang
Published: November 27,2025
Abstract
Objective: To explore the efficacy and safety of recombinant human interferon alpha-2b combined with hydroxyurea tablets in the treatment of myeloproliferative neoplasms (MPN). Methods: The study included 90 patients admitted between January 2019 and August 2024, all diagnosed with MPN. Patients were randomly divided into a control group and an observation group, each consisting of 45 patients. The control group received hydroxyurea tablets, while the observation group received recombinant human interferon alpha-2b combined with hydroxyurea tablets. Clinical treatment outcomes, changes in blood parameters (hemoglobin [HGB], platelet count [PLT]), and adverse reactions were compared between the two groups. Results: The total clinical effectiveness rate was higher in the observation group than in the control group (P < 0.05). After treatment, HGB and PLT levels were lower in the observation group compared to the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion: Recombinant human interferon alpha-2b combined with hydroxyurea tablets improves clinical treatment outcomes and HGB and PLT levels in MPN patients, demonstrating high safety.
Keywords
Recombinant human interferon alpha-2b; hydroxyurea tablets; MPN; efficacy; safety
References
[1] Barouqa M, McPhail ED. Sclerosing extramedullary hematopoietic tumor in chronic myeloproliferative neoplasms. Blood. 2022 Jun 2;139(22):3345.
[2] Bermes M, Rodriguez MJ, de Toledo MAS, et al. Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms. Int J Mol Sci. 2023 Dec 16;24(24):17560.
[3] Hu HP. Efficacy Analysis of Hydroxyurea Combined with Pegylated Interferon Alpha-2a in the Treatment of Myeloproliferative Disorders. Contemp Med Forum. 2021;19(21):131-3.
[4] Liu XN, Wu BW. Clinical Efficacy Observation of Imatinib Combined with Recombinant Human Interferon Alpha-2b in the Treatment of Newly Diagnosed Chronic Myeloid Leukemia. J Med Sci Metall Ind. 2022;39(1):17-8.
[5] Lu TT. Observation of Clinical Efficacy of Hydroxyurea Combined with Recombinant Human Interferon Alpha-2b in the Treatment of Myeloproliferative Neoplasms. Res Chin Foreign Med. 2023;2(33):61-3.
[6] Luo DM, Luo J, Liang HY, et al. Efficacy and Safety of Pegylated Interferon Alpha-2b in the Treatment of Myeloproliferative Tumors. J South Med Univ. 2023;43(6):1029-34.
[7] National Administration of Traditional Chinese Medicine. Guidelines for Clinical Research of New Chinese Medicines. Beijing: China Medical Science and Technology Press; 2002. p. 215-6.
[8] Viaud M, Abdel-Wahab O, Gall J, et al. ABCA1 Exerts Tumor-Suppressor Function in Myeloproliferative Neoplasms. Cell Rep. 2020 Mar 10;30(10):3397-410.
[9] Wang H, Li YC, Gao QY, et al. Efficacy of Imatinib Combined with Recombinant Human Interferon Alpha-2b in Patients with Accelerated Phase Chronic Myeloid Leukemia and Its Impact on Serum MMP-2, SALL4 mRNA, and AGP Levels. Chin J Clin New Med. 2023;16(5):468-73.
[10] Yue Min Gong, Guang Sheng He. New Nomenclature and Classification of Myelodysplastic Neoplasms by WHO in 2022. Chin J Pract Intern Med. 2022;42(9):737-41.
How to cite this paper
Efficacy and Safety Analysis of Recombinant Human Interferon Alpha-2b Combined with Hydroxyurea Tablets in the Treatment of MPN
How to cite this paper: Yigang Guo, Lulu Zhang, Ping Hu, Xiu Guo, Rongyao Zhang, Na Li, Qiong Yi, Xu Chen. (2025) Efficacy and Safety Analysis of Recombinant Human Interferon Alpha-2b Combined with Hydroxyurea Tablets in the Treatment of MPN. International Journal of Clinical and Experimental Medicine Research, 9(6), 619-622.
DOI: http://dx.doi.org/10.26855/ijcemr.2025.11.006